CPSI VS MCRB Stock Comparison
Performance
CPSI10/100
10/100
CPSI returned -59.89% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
MCRB10/100
10/100
MCRB returned -79.71% in the last 12 months. Based on SPY's performance of -20.74%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
CPSI52/100
52/100
11 analysts offer 12-month price targets for CPSI. Together, they have an average target of 0, the most optimistic target put CPSI at 0 within 12-months and the most pessimistic has CPSI at 0.
MCRB78/100
78/100
9 analysts offer 12-month price targets for MCRB. Together, they have an average target of 0, the most optimistic target put MCRB at 0 within 12-months and the most pessimistic has MCRB at 0.
Technicals
CPSI14/100
14/100
CPSI receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
MCRB11/100
11/100
MCRB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
CPSI10/100
10/100
CPSI has missed earnings 8 times in the last 20 quarters.
MCRB10/100
10/100
MCRB has missed earnings 10 times in the last 20 quarters.
Profit
CPSI64/100
64/100
Out of the last 20 quarters, CPSI has had 18 profitable quarters and has increased their profits year over year on 7 of them.
MCRB13/100
13/100
Out of the last 20 quarters, MCRB has had 2 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
CPSI31/100
31/100
CPSI has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.
MCRB46/100
46/100
MCRB has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.
Dividend
CPSI37/100
37/100
CPSI's most recent dividend was $0.10 per share, based on a share price of $11.36. It was a payout ratio of 18.57% compared to their total earnings.
MCRB
"Dividend" not found for MCRB
Sentiment
CPSI
"Sentiment" not found for CPSI
MCRB65/100
65/100
MCRB had a bullish sentiment score of 65.24% across Twitter and StockTwits over the last 12 months. It had an average of 33.11 posts, 26.15 comments, and 103.76 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Computer Programs & Systems In Summary
Nasdaq / CPSI
Healthcare
Health Information Services
Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital, and provide software applications. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions. It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.
Seres Therapeutics, Inc. Summary
Nasdaq / MCRB
Healthcare
Biotechnology
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CPSI to other companies in the same or a similar industry.